![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 21, 2025
An update on the NCTN Grant; upcoming Group Meeting highlights; a perspective on the mistrust of science
March 21, 2025
The changes significantly broaden eligibility and clarify key details in this phase 3 trial exploring whether adding radiation therapy to standard immunotherapy will improve survival in patients with stable disease after initial treatment
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
March 21, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
February 19, 2025
The co-chairs highlight the immense value of Cooperative Group cancer research and the importance of its continued funding
February 19, 2025
This is the first randomized phase 3 study to evaluate autologous stem cell transplantation in patients with this rare and aggressive form of non-Hodgkin lymphoma
February 19, 2025
Patient-reported outcomes research has led to many discoveries that have influenced current research priorities and the way the Group designs its trials
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
February 19, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
June 25, 2025
This clinical trial is evaluating a new drug combination for patients with B-cell lymphoma that has relapsed after remission or no longer responds to standard treatment